In animal models of non-renovascular CKD, VEGF treatment has been shown to preserve the microvascular architecture, and it stimulates endothelial progenitor cells, which in turn leads to more stable renal function and slowing of disease progression [43,44]. Here, VEGFA is linked to chronic kidney disease.